Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

[1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-E386

[2] Soerjomataram I(2002)Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 ( Cancer Res 62 4617-4622

[3] Dikshit R(2010) = 3424) Expert Rev Mol Diagn 10 947-962

[4] Harbeck N(2013)Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 Int J Cancer 132 2404-2412

[5] Kates RE(2015)Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002 Ann Oncol 26 1533-1546

[6] Look MP(2015)Tailoring therapies—improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015 Genet Med 17 519-532

[7] Mengele K(2007)Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews J Clin Oncol 25 5287-5312

[8] Napieralski R(2014)American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer Breast Cancer Res BCR 16 428-1835

[9] Magdolen V(2013)uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies Eur J Cancer 49 1825-920

[10] Allemani C(2001)Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients J Natl Cancer Inst 93 913-128

[1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-E386

[2] Soerjomataram I(2002)Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 ( Cancer Res 62 4617-4622

[3] Dikshit R(2010) = 3424) Expert Rev Mol Diagn 10 947-962

[4] Harbeck N(2013)Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 Int J Cancer 132 2404-2412

[5] Kates RE(2015)Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002 Ann Oncol 26 1533-1546

[6] Look MP(2015)Tailoring therapies—improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015 Genet Med 17 519-532

[7] Mengele K(2007)Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews J Clin Oncol 25 5287-5312

[8] Napieralski R(2014)American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer Breast Cancer Res BCR 16 428-1835

[9] Magdolen V(2013)uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies Eur J Cancer 49 1825-920

[10] Allemani C(2001)Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients J Natl Cancer Inst 93 913-128